HomeCompareDMTK vs ORCC

DMTK vs ORCC: Dividend Comparison 2026

DMTK yields 2127.66% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DMTK wins by $17707088693.35M in total portfolio value
10 years
DMTK
DMTK
● Live price
2127.66%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17707088693.38M
Annual income
$16,208,512,607,342,262.00
Full DMTK calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — DMTK vs ORCC

📍 DMTK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDMTKORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DMTK + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DMTK pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DMTK
Annual income on $10K today (after 15% tax)
$180,851.06/yr
After 10yr DRIP, annual income (after tax)
$13,777,235,716,240,922.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, DMTK beats the other by $13,777,235,716,240,922.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DMTK + ORCC for your $10,000?

DMTK: 50%ORCC: 50%
100% ORCC50/50100% DMTK
Portfolio after 10yr
$8853544346.70M
Annual income
$8,104,256,303,671,132.00/yr
Blended yield
91.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

DMTK
Analyst Ratings
3
Buy
4
Hold
Consensus: Hold
Price Target
$7.50
+7878.7% upside vs current
Range: $7.50 — $7.50
Altman Z
-8.4
Piotroski
4/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DMTK buys
0
ORCC buys
0
No recent congressional trades found for DMTK or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDMTKORCC
Forward yield2127.66%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$17707088693.38M$21.4K
Annual income after 10y$16,208,512,607,342,262.00$1.04
Total dividends collected$17601219228.91M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy
Analyst price target$7.50$16.00

Year-by-year: DMTK vs ORCC ($10,000, DRIP)

YearDMTK PortfolioDMTK Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$223,466$212,765.96$11,190$489.61+$212.3KDMTK
2$4,682,655$4,443,546.58$12,229$256.01+$4.67MDMTK
3$92,031,981$87,021,539.62$13,216$130.74+$92.02MDMTK
4$1,696,889,334$1,598,415,114.79$14,207$66.02+$1696.88MDMTK
5$29,359,261,977$27,543,590,390.03$15,234$33.17+$29359.25MDMTK
6$476,792,027,971$445,377,617,654.91$16,317$16.62+$476792.01MDMTK
7$7,269,883,644,738$6,759,716,174,809.65$17,468$8.32+$7269883.63MDMTK
8$104,104,693,867,782$96,325,918,367,911.80$18,695$4.16+$104104693.85MDMTK
9$1,400,538,398,162,041$1,289,146,375,723,514.20$20,006$2.08+$1400538398.14MDMTK
10$17,707,088,693,375,648$16,208,512,607,342,262.00$21,407$1.04+$17707088693.35MDMTK

DMTK vs ORCC: Complete Analysis 2026

DMTKStock

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

Full DMTK Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this DMTK vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DMTK vs SCHDDMTK vs JEPIDMTK vs ODMTK vs KODMTK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.